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Moving forward to address key
unanswered questions on targeting PD-1/
PD-L1 in cancer: limitations in preclinical
models and the need to incorporate
human modifying factors
Catherine T. Le1 and William J. Murphy1,2*
Abstract
The tremendous clinical success of immune checkpoint inhibition (ICI), particularly targeting the programmed cell
death protein 1 (PD-1)/programmed death-ligand 1/2 (PD-L1/2) pathway, has resulted in application to multiple
cancers, as a monotherapy and as a companion to both conventional and novel agents. Despite this, the precise
mechanisms underlying the anti-tumor effects of PD-1/PD-L1 blockade remain unclear. Emphasis has centered on
its reversal of tumor-specific CD8+ T-cell exhaustion, although many cell types and processes are likely impacted.
Due to the complex and pervasive roles of PD-1/PD-L1 on T-cell biology, including on initial T-cell priming, PD-1
blockade likely affects all aspects of T- cell responses, and these other effects may be even more critical for durable
anti-tumor responses. Delineating these complex interactions necessitates in vivo modeling. By far, the healthy,
young and inbred laboratory mouse, transplanted with an extensively cultured tumor cell line, has been the
predominant preclinical model used to assess potential therapeutic efficacies. However, these mouse models often
do not adequately reflect the tumor progression and cellular and genetic heterogeneity found within human
cancers. Furthermore, laboratory mice also present with a vastly restricted immune profile compared to humans.
This commentary discusses some of the critical questions that need to be addressed to optimize the use of ICI as
well as caveats and limitations for consideration when extrapolating preclinical mouse data to the human cancer
scenario.
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The recent successes and improved safety profiles of ICI
in cancer therapy, particularly targeting programmed cell
death protein 1 (PD-1) and its ligands (PD-L1/2), have
resulted in approval for several solid and hematologic
malignancies, even as first-line therapy [1]. Other prom-
ising ICI in development include blockade therapy
against T-cell immunoglobulin and mucin-domain
containing-3 (TIM3), Lymphocyte-activation gene 3
(LAG3), and T-cell immunoreceptor with Ig and ITIM
domains (TIGIT). In addition, combination approaches
targeting both cytotoxic T-lymphocyte-associated pro-
tein 4 (CTLA-4) and PD-1/PD-L1 are being assessed
clinically. As adoptive T-cell therapies, including
chimeric antigen receptor (CAR) T-cell therapies, are
being used increasingly, efforts have been directed to
augment persistence and function of tumor-specific T
cells [2]. Clinical success has generated increased atten-
tion regarding mechanisms of action. Such insights
could optimize and shift therapeutic application for
greater efficacy and outcome as well as reduce potential
toxicities. Critical questions remain on how, when, and
to whom ICI should be applied and on potential effects,
both positive and negative, when combined with other
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modalities. Questions also remain on what the proper
duration of ICI therapy is and, if therapy is discontinued,
how long are the effects of ICI therapy maintained. This
is especially pertinent given the property of many can-
cers to become dormant and evade immune attack and
the well-reported decline in immune function with age.
All of which could mean that cessation of immunother-
apy, even in cases of complete responses, could be
viewed as a potential risk for relapse. Finally, under-
standing the long-term impact of ICI on the overall im-
mune status is critical, especially in older individuals,
who have a finite memory T-cell pool. Preclinical mouse
models are invaluable tools that can address some of
these pressing questions. However, aside from inherent
species differences and the difficulty of assessing im-
mune effects using xenogeneic models, other critical
caveats need to also be considered. Understanding the
advantages and disadvantages inherent to mouse preclin-
ical tumor modeling is, therefore, paramount in moving
forward with PD-1/PD-L1 targeting in cancer therapy.
Diverse role of PD-1/PD-L1 signaling on T cells
The initial goal of PD-1/PD-L1 targeting in cancer cen-
tered on reinvigorating tumor-specific but functionally
exhausted memory CD8+ T cells. T-cell exhaustion,
originally described in chronic viral infection models,
denotes a state of chronic antigen exposure that impairs
the transition from effector to memory state. Exhaustion
is an umbrella term that demarcates specific properties:
co-expression of one or more inhibitory receptors (i.e.
PD-1, TIM3, LAG3), reduced proliferative capability,
and decreased cytokine production (tumor necrosis fac-
tor, interferon-gamma) and effector functions [3]. T-cell
exhaustion can result from chronic antigen stimulation
but may also be induced by other immunosuppressive
pathways, such as inflammatory tissue microenviron-
ment, presence of regulatory immune cell populations,
and other inhibitory signals from cytokines and recep-
tors [3]. The expression of PD-1 itself is not solely a
marker of exhaustion, as PD-1 is also rapidly upregu-
lated by naïve T cells upon initial activation [1, 3].
Therefore, determination of T-cell exhaustion necessi-
tates the assessment of functional readouts. PD-1 has
been demonstrated to decrease CD28 co-stimulatory sig-
naling, which reinforces the concept that PD-1 is in-
volved in both initial naïve T-cell priming and memory
T-cell exhaustion [4]. Initial work on the role of PD-1 in
T-cell exhaustion were performed using viral response
models. Studies utilizing chronic lymphocytic choriome-
ningitis virus (LCMV) infection in mice highlighted the
ability of PD-L1 blockade to reverse exhaustion of
LCMV-specific CD8+ T-cells [5]. However, PD-1 knock-
out mice infected with chronic LCMV surprisingly had
greater accumulation of dysfunctional T cells and
decreased memory maintenance suggesting that PD-1
also has a potentially important role in allowing memory
T cells to persist in the presence of chronic antigen
stimulation [6]. Some mouse models employ transient
CD4 depletion to augment the exhausted phenotype in
the CD8+ T-cell pool [5, 6]. However, CD4+ T cell de-
pletion has been demonstrated to negatively impact
CD8+ T-cell priming in a phenomenon termed “help-
lessness,” and while “helplessness” may result in many of
the same characteristics as “exhaustion,” it remains un-
clear what the commonalities are in these two pathways.
Considering the diverse functions of the PD-1/PD-L1
pathway on T-cell biology, it is not known if blockade is
effective primarily by reversing T-cell exhaustion on
memory T cells or augmenting priming and epitope-
spreading of naïve T cells. Promoting priming may allow
for continuous adaptation to cancer, which is genetically
unstable and immune evading. Likely, both processes are
contributing to the long-term successes of ICI in some
patients but may be dependent on both the timing of
the therapy and the genetic stability of the cancer.
Thus, given the ever-increasing application of ICI to
PD-1/PD-L1 in many cancer regimens, even as front-
line therapy, it is imperative to more thoroughly under-
stand the precise mechanisms of action. Preclinical
mouse models in immunology predominantly use block-
ing or depleting monoclonal antibodies or genetic dele-
tion to ascertain function of a molecule or pathway.
Limitations of these approaches arise due to incomplete-
ness of blockade, unintended effects on other cell types,
unpredicted compensatory pathways, or negative effects
on normal development or immune cell differentiation.
Effective use of monoclonal antibodies or small mole-
cules is also dependent on pharmacokinetics, optimal
exposure, and inherent antagonistic versus agonistic
properties, which may not be mutually exclusive. An-
other important caveat in preclinical mouse cancer
immunotherapy models is related to the lack of “muri-
nized” reagents analogous to humanized reagents used
in patients. Preclinical models often necessitate the use
of xenogeneic antibodies, which will elicit a range of im-
mune responses, including neutralizing antibodies and,
in some cases, fatal anaphylaxis with repeated applica-
tion of rat or hamster monoclonal antibodies to mouse
PD-1 [7]. As the impact of long-term immunotherapy in
most preclinical tumor models cannot be determined
with xenogeneic reagents, the ability to use mouse re-
agents becomes more important to model the potential
long-term effects of ICI. One way to possibly model
human ICI reagents in vivo is the utilization of
“humanized” mice, either created through the reconsti-
tution of immunodeficient mice with human cells or
“humanization” of specific checkpoints in immunocom-
petent mice [8]. However, the xenogeneic environment
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has profound effects on human immune cell develop-
ment, engraftment and function, which can confound
interpretation of the data when modeling primary human
immune responses to weakly immunogenic, autologous
tumors or worse yet, allogeneic human tumor lines.
Another uncertainty surrounding the mechanism of
PD-1/PD-L1 blockade concerns the widespread expres-
sion of these molecules on various immune cells as well
the cancer itself. While PD-1 has been extensively de-
scribed on T cells, there are reports of PD-1 on natural
killer (NK) cells, B cells, and monocytes [1]. Indeed,
studies using PD-1 knockout mice detail abnormalities
in B cell function and neutrophil response [9, 10].
Caution must be exercised when assessing PD-1/PD-L1
expression solely by flow cytometry. It has been recently
reported that non-specific binding of PD-1 antibodies by
dead or dying cells can occur, leading to possible false-
positive results [11]. Furthermore, PD-L1 can be ubiqui-
tously expressed by all cells under inflammatory and
activating conditions [1]. It, therefore, remains unclear
with PD-1/PD-L1 blockade if the resulting or indirectly/
or indirectly on T cells.
Limitations of preclinical modeling in reflecting
human cancer progression and host factors
The overwhelming majority of preclinical tumor studies
utilize fully transformed, extensively cultured, rapidly
growing (growth fraction is usually 100%), and relatively
homogeneous tumor cell lines. These tumor cell lines
are typically engrafted into healthy, young (usually 8–10
weeks old, analogous to a young human adolescent),
genetically identical, and inbred laboratory mice. Be-
cause research mice are housed under strict specific-
pathogen-free (SPF) conditions, even a “middle-aged”
mouse presents as immunologically naïve and immature,
especially when compared to mice housed under “dirty”
conditions [12]. The naïve immune system can readily
respond to undefined and highly immunogenic determi-
nants on tumor cell lines, particularly when injected into
subcutaneous tissues which result in tissue damage and
subsequent toll receptor triggering. Though tumor lines
used are considered syngeneic, immunogenicity still is
evident and unpredictable due to extensive culturing.
Differences between tumor cell lines and mouse strains
are highlighted even more so when considering varia-
tions between vendors due to genetic drift. Tumor lines
that are transformed to express viral or xenogeneic anti-
gens, such as ovalbumin (OVA), to monitor putative
“tumor-specific” T-cells elicit strong primary and poten-
tially artefactual T-cell responses. The tumor cell lines,
due to extensive in vitro passaging under confluent con-
ditions, are homogeneous and undergo massive cell
death during in vivo engraftment. This is reflected in the
tumor growth kinetics, where a lag period of a week or
two is followed by extremely rapid growth. When the tu-
mors are implanted subcutaneously, clinical survival is
due to primary tumor size or necrosis and rarely metas-
tasis. Immune resistance to tumor growth, therefore,
represents an acute response to engraftment. This sug-
gests that ICI efficacy in preclinical models may be due
to an augmentation of a primary response rather than
reversal of T-cell exhaustion since immune evasion by
the tumor would not be necessary until later. This is in
stark contrast to the chronic viral models, which can
take over 6 weeks to establish T-cell exhaustion follow-
ing infection. Thus, the “exhausted” phenotype observed
during this acute primary response to a tumor line is
unlikely to reflect the “exhausted” phenotype observed
in human patients, where cancer may have been pro-
gressing for years, is vastly heterogeneous, and employs
numerous immune evasion mechanisms.
In preclinical models, ICI treatment is sometimes initi-
ated at the time or soon after the tumor injection, such
that the animal’s tumor burden is minimal compared to
the human cancer scenario. The initiation of ICI in human
cancer patients begins in a setting where immune evasion
has already occurred and where both priming and
exhaustion of T cells are possibly simultaneously occur-
ring (Fig. 1). Modeling slower growing or spontaneous tu-
mors, such as in genetically engineered mouse (GEM)
models, would better mirror the human cancer scenario
but are difficult to use in therapeutic intervention studies
due to heterogeneity in tumor growth. This necessitates
large sample sizes and higher cost. However, in the end,
such approaches may yield more robust and meaningful
data for our understanding of the most effective applica-
tion of cancer immunotherapy regimens in humans.
While the predominant emphasis in cancer therapy
has centered on the cancer, a key component integral
for immunotherapy efficacy is the immune status of the
patient with age being a driving factor. Given that the
median age of cancer diagnosis is 66 years of age,
according to NCI’s Surveillance, Epidemiology, and End
Results Program, the differences in the T-cell memory
compartment are stark when comparing young (8–10
weeks) to aged (> 16 months) inbred mice housed under
SPF conditions. Likewise, the human immune system is
dynamic and changes with exposure to multiple infec-
tions, environmental factors, age, thymic involution, and
other host factors; yet, these elements are often not
modeled but likely influence ICI response and tumor
growth. As both the memory T-cell compartment and
PD-1/PD-L1 expression increases with age and with
presence of chronic or latent viral infection, such as
CMV and EBV, the fact that the majority of mouse
models do not mirror these conditions is a concern
when attempting to extrapolate immune therapy effects
to the clinical scenario [13].
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In addition, other human modifying factors such as
diet, sex, age, gut microbiome, co-morbidities and adi-
posity can influence immune responses and cancer
immunotherapy outcome [14–17]. We have observed
that obesity has a profound impact on T-cell phenotype
and function in mice, dogs, non-human primates, and
humans [15]. Furthermore, although obesity promoted
PD-1-mediated T-cell exhaustion as well as tumor pro-
gression, it also paradoxically promoted anti-tumor re-
sponses to PD-1 blockade in mice and was associated
with increased progression-free survival clinically [15].
Other clinical studies have reported an impact of gender
on outcome as well, highlighting the critical importance
of incorporating human modifying factors in preclinical
models [14]. However, like GEM models, the incorpor-
ation of human modifying factors, such as age, sex, or
obesity, adds tremendous time and cost. Although initial
preclinical studies with young, inbred SPF mice are cost-
effective to determine early dosing and timing and to
delineate efficacy versus toxicities, these models are
simply not sufficient to directly extrapolate with regard
to efficacy. This is particularly pertinent given the off-
target effects and potentially life-threatening toxicities
that have been reported with ICI as well as other
immune-based therapies. Although key differences be-
tween mice and humans will always exist, it is imperative
to more critically incorporate these human modifying
elements into cancer immunotherapy models in order to
more reliably predict clinical outcomes (both positive
and negative). This can be done by employing more
complex mouse modeling to better mirror potential
effects of immune-based interventions.
Conclusions
Mouse models have been paramount to the discovery of
immune checkpoints and the advancement of ICI. Des-
pite these breakthroughs, interpretation of preclinical
studies of PD-1/PD-L1 blockade in mice is complicated
by several factors. First, and most notably, while the PD-
1/PD-L1 pathway has a more defined role in T-cell
exhaustion, effects on T-cell priming and other immune
cell responses remain largely unknown. Second, there
are currently unresolved effects of immune and host-
factor differences between young, SPF mice and human
cancer patients that can skew interpretation of results.
However, moving forward, sex, diet, age, prior infectious
challenges, and housing conditions are adjustable vari-
ables that, together with the ease and speed of rodent
modeling, can be an important investigational tool.
While utilization of these modifying conditions can
indeed be very costly, they can provide important
insights that facilitate translation of the preclinical
observations to patients.
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